Brief: Aelis Farma H1 Net Result Turns To Loss Of 10.4 Million Euros
Sept 26 (Reuters) - Aelis Farma SA AELIS.PA :
* STRONG CASH POSITION OF €39.8M AT 30 JUNE 2022
* H1 2022 MARKED BY THE START OF ENROLMENT IN THE PHASE 2B
STUDY
WITH AEF0117 IN THE TREATMENT OF CANNABIS ADDICTION
* H1 NET LOSS EUR 10.4 MILLION VERSUS PROFIT EUR 3.8 MILLION
YEAR
AGO
* H1 OPERATING LOSS EUR 4.6 MILLION VERSUS LOSS EUR 4.7
MILLION
YEAR AGO
Further company coverage: AELIS.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Aelis Farma SA
See all newsBrief: Aelis Farma Availability Of 2025 Half-Year Financial Report
Brief: Euronext: Quarterly Review Of CAC Family
Brief: Aelis Farma Confirms Its 2025 Outlook
Brief: Aelis Farma Announces The Final Analysis Of Phase 2B Clinical Trial In Cannabis Use Disorder With AEF0117
Brief: Aelis Farma Says AEF0217 Well Tolerated With No Safety Concerns Identified